Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$111.00 USD
+0.06 (0.05%)
Updated Aug 16, 2024 03:59 PM ET
After-Market: $111.00 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.00 USD
+0.06 (0.05%)
Updated Aug 16, 2024 03:59 PM ET
After-Market: $111.00 0.00 (0.00%) 5:30 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Markets Mixed as Q1 Earnings, Powell Control News Headlines
by Mark Vickery
Wednesday morning brings us more Q1 earnings reports, including from Abbott Labs (ABT) and U.S. Bancorp (USB).
3 Buy Rated Stocks to Consider as Earnings Approach
by Shaun Pruitt
Several top-rated Zacks stocks are standing out before their first-quarter earnings report next week and here are three to consider.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott (ABT) is likely to have progressed with its initiative to commercialize several biosimilars in emerging markets.
Ahead of Abbott (ABT) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Abbott (ABT) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Medtronic's (MDT) Sphere-360 PFA Study Outcome Favorable
by Zacks Equity Research
Medtronic's (MDT) Sphere-360 catheter is designed to simplify the atrial fibrillation process while increasing efficiency and giving long-lasting lesions.
Abbott (ABT) Rises Higher Than Market: Key Facts
by Zacks Equity Research
The latest trading day saw Abbott (ABT) settling at $112.44, representing a +1.74% change from its previous close.
HAE vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
HAE vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
by Zacks Equity Research
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services
by Zacks Equity Research
T-Mobile US, Abbott Laboratories, Palo Alto Networks, Enterprise Products Partners and The PNC Financial Services are part of the Zacks top Analyst Blog.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Top Analyst Reports for T-Mobile US, Abbott Laboratories & Palo Alto Networks
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
by Zacks Equity Research
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval
by Zacks Equity Research
Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.
Abbott (ABT) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close.
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark
by Zacks Equity Research
Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Abbott (ABT) stood at $111.50, denoting a +1.35% change from the preceding trading day.
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Abbott (ABT) Expands in Canada With First Eterna SCS Use
by Zacks Equity Research
Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.
Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apyx (APYX) delivered earnings and revenue surprises of -46.15% and 1.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Abbott (ABT) closed at $111.50 in the latest trading session, marking a -1.47% move from the prior day.
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
In the most recent trading session, Abbott (ABT) closed at $113.16, indicating a +0.64% shift from the previous trading day.
Here's Why Investors Should Retain Abbott (ABT) Stock Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.